| Multiple Myeloma
Darzalex vs Empliciti
Side-by-side clinical, coverage, and cost comparison for multiple myeloma.Deep comparison between: Darzalex vs Empliciti with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEmpliciti has a higher rate of injection site reactions vs Darzalex based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Empliciti but not Darzalex, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Darzalex
Empliciti
At A Glance
IV infusion
Weekly to every 4 weeks
Anti-CD38 monoclonal antibody
IV infusion
Weekly to every 4 weeks
SLAMF7 antagonist
Indications
- Multiple Myeloma
- Multiple Myeloma
Dosing
Multiple Myeloma 16 mg/kg IV; dosing schedule varies by combination regimen: weekly for initial doses (6-9 doses), then every 2-3 weeks, then every 4 weeks until disease progression; pre-medicate with corticosteroids, antipyretics, and antihistamines before each infusion.
Multiple Myeloma (with lenalidomide and dexamethasone) 10 mg/kg IV weekly for cycles 1 and 2 (28-day cycles), then 10 mg/kg every 2 weeks until disease progression or unacceptable toxicity.
Multiple Myeloma (with pomalidomide and dexamethasone) 10 mg/kg IV weekly for cycles 1 and 2 (28-day cycles), then 20 mg/kg every 4 weeks until disease progression or unacceptable toxicity.
Contraindications
- History of severe hypersensitivity (e.g., anaphylactic reactions) to daratumumab or any of the formulation components
—
Adverse Reactions
Most common (>=20%) Upper respiratory infection, neutropenia, infusion-related reactions, thrombocytopenia, diarrhea, constipation, anemia, peripheral sensory neuropathy, fatigue, peripheral edema, nausea, cough, pyrexia, dyspnea, asthenia
Serious Pneumonia, infusion-related reactions (Grade 3-4), neutropenia, thrombocytopenia, febrile neutropenia, sepsis
Postmarketing Anaphylactic reaction, infusion-related reactions (including deaths), pancreatitis, cytomegalovirus, listeriosis
Most common (>=10%) Fatigue, diarrhea, pyrexia, constipation, cough, peripheral neuropathy, nasopharyngitis, upper respiratory tract infection, decreased appetite, pneumonia, pain in extremities, headache, vomiting, weight decreased, lymphopenia, cataracts, oropharyngeal pain
Serious Pneumonia, pyrexia, respiratory tract infection, anemia, pulmonary embolism, acute renal failure
Pharmacology
Anti-CD38 monoclonal antibody; daratumumab is an IgG1k human mAb that binds CD38 on tumor cells and induces apoptosis via Fc-mediated cross-linking and immune-mediated lysis through complement dependent cytotoxicity (CDC), antibody dependent cell mediated cytotoxicity (ADCC), and antibody dependent cellular phagocytosis (ADCP).
Elotuzumab is a humanized IgG1 monoclonal antibody that targets SLAMF7 on myeloma cells and natural killer (NK) cells, directly activating NK cells through the SLAMF7 pathway and mediating killing of myeloma cells via antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Darzalex
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
Empliciti
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Darzalex
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Empliciti
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Darzalex
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Empliciti
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Acute Lymphoblastic Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Bristol-Myers Squibb Patient Assistance Foundation (BMSPAF)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DarzalexView full Darzalex profile
EmplicitiView full Empliciti profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.